A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Gut microbe-derived methane may slow colon transit causing chronic constipation (CC). Effect of rifaximin on breath methane and slow-transit CC was evaluated. METHOD: Bristol stool form, frequency, colon transit time (CTT), and breath methane were evaluated in 23 patients with CC (10 patients with constipation-predominant irritable bowel syndrome [IBS-C], 13 functional constipation, Rome III) and m-ethane production compared with 68 non-constipating IBS. Methane-producing CC (basal ≥ 10 PPM and/or post-lactulose rise by > 10 PPM) was randomized (double-blind) to rifaximin (400-mg thrice/day, 2-weeks) or placebo. Stool forms, frequency, breath methane, and CTT were recorded afterward. RESULTS: CC patients tended to be methane producer more often (13/23 [56.5%] vs. 25/68 [36.5%], p = 0.07) and had greater area under curve (AUC) for methane (2415 [435-23,580] vs. 1335 [0-6562.5], p = 0.02) than non-constipating IBS. Methane producers (8/13 [61.5%]) and 5/10 (50%) non-producers had abnormal CTT (marker retention: 36-h, 53 [0-60] vs. 19 [8-56], p = 0.06; 60-h, 16 [0-57] vs. 13 [3-56], p = 0.877). Six and 7/13 methane producers were randomized to rifaximin and placebo, respectively. Rifaximin reduced AUC for methane more (6697.5 [1777.5-23,580] vs. 2617.5 [562.5-19,867.5], p = 0.005) than placebo (3945 [2415-12,952.5] vs. 3720 [502.5-9210], p = 0.118) at 1 month. CTT normalized in 4/6 (66.7%) on rifaximin (36-h retention, 54 [44-57] vs. 36 [23-60], p = 0.05; 60-h, 45 [3-57] vs. 14 [11-51], p = 0.09) but none on placebo (p = 0.02) (36-h, 31 [0-60] vs. 25 [0-45], p = 0.078; 60-h, 6 [0-54] vs. 12 [0-28], p = 0.2). Weekly stool frequency (3 [1-9] and 7 [1-14], p = 0.05) and forms improved with rifaximin than placebo. CONCLUSION: Rifaximin improves CC by altering methane production and colon transit. TRIAL REGISTRATION: Clinical Trial Registry, India: REF/2012/01/003216 ᅟ ᅟ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508
Parthasarathy, G., Chen, J., Chen, X., Chia, N., O'Connor, H. M., Wolf, P. G., Gaskins, H. R., & Bharucha, A. E. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.005 · Cited by 396
The Intestinal Microenvironment and Functional Gastrointestinal Disorders
Barbara, G., Feinle-Bisset, C., Ghoshal, U. C., Santos, J., Vanner, S. J., Vergnolle, N., Zoetendal, E. G., & Quigley, E. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.028 · Cited by 335
Self-citationLembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310 · cited 1×
“The dose of rifaximin was also lower than used currently in practice and in randomized controlled trials on IBS [23, 24].”
MethodAttaluri, A., Jackson, M., Valestin, J., & Rao, S. S. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.655 · Cited by 261
Methanogens, Methane and Gastrointestinal Motility
Triantafyllou, K., Chang, C., & Pimentel, M. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2014.20.1.31 · Cited by 254
Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3157-8 · Cited by 143
Lee, K.-M., Paik, C.-N., Chung, W. C., Yang, J.-M., & Choi, M.-G. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835eb916 · Cited by 59
The effects and mechanism of action of methane on ileal motor function
Park, Y. M., Lee, Y. J., Hussain, Z., Lee, Y. H., & Park, H. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13077 · Cited by 27
Cited by
Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders
Singh, R., Zogg, H., Wei, L., Bartlett, A., Ghoshal, U. C., Rajender, S., & Ro, S. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20149 · Cited by 259
Self-citationHammer, H. F., Fox, M. R., Keller, J., Salvatore, S., Basilisco, G., Hammer, J., Lopetuso, L., Benninga, M., Borrelli, O., Dumitrascu, D., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12133 · Cited by 189
Pan, R., Wang, L., Xu, X., Chen, Y., Wang, H., Wang, G., Zhao, J., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14183704 · Cited by 149
“A randomized controlled trial (RCT) indicated that a reduction in methane production with antibiotic treatment directed against methanogenic bacteria in the gut might accelerate colonic transit leading to improvement in constipation [70].”
Background
Metadata
- Authors
- Ghoshal, U. C., Srivastava, D., & Misra, A.
- Venue
- Indian Journal of Gastroenterology
- Published
- 2018-09
- Volume
- 37
- Issue
- 5
- Pages
- 416-423
- ISSN
- 0254-8860 (ISSN-L)
- 0975-0711
- OpenAlex
- W2900108584
- Cited by
- 56
- References
- 10
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. https://app.cochat.ai/papers/10.1007/s12664-018-0901-6
- The paper
- Ghoshal, U. C., Srivastava, D., & Misra, A. (2018). A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. Indian Journal of Gastroenterology. https://doi.org/10.1007/s12664-018-0901-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.